Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study
Aim. The Hyper-CVAD regimen has shown promising results for adult patients with acute lymphoblastic leukemia (ALL), as designed by the MD Anderson Cancer Center (MDACC). This treatment has resulted in a complete remission rate of 92% and a 5-year overall survival of 38%. However, given the diversity...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2023/5593635 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547938435334144 |
|---|---|
| author | Zahra Malakoutikhah Farzaneh Ashrafi Ali Derakhshandeh |
| author_facet | Zahra Malakoutikhah Farzaneh Ashrafi Ali Derakhshandeh |
| author_sort | Zahra Malakoutikhah |
| collection | DOAJ |
| description | Aim. The Hyper-CVAD regimen has shown promising results for adult patients with acute lymphoblastic leukemia (ALL), as designed by the MD Anderson Cancer Center (MDACC). This treatment has resulted in a complete remission rate of 92% and a 5-year overall survival of 38%. However, given the diversity of patient demographics and institutional methods, outcomes may differ between various institutions. This study will compare the outcome of adult ALL patients treated with the Hyper-CVAD regimen in Iran with those obtained in the original series presented at the MDACC. Patients and Method. In this retrospective study, we evaluated the 2-year leukemia-free survival (LFS) and the 2-year overall survival (OS) of 70 ALL patients treated between 2014 and 2019 in the Seyed Al-Shohada Hospital in Isfahan, Iran. Results. In total, 59 ALL patients (84.28%) achieved complete remission (CR). The CR rate had statistical differences by bone marrow transplantation (BMT) and WBC count. The 2-year LFS and OS were 40% and 42%, respectively. There were significant differences in LFS and OS by BMT, myeloid marker, and WBC count. Conclusion. The outcome of the traditional Hyper-CVAD regimen in treating adult ALL was not satisfying. More efficient therapies should be applied for the treatment of adult ALL. |
| format | Article |
| id | doaj-art-a502f21a958744478359532dea715ed1 |
| institution | Kabale University |
| issn | 1687-9112 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-a502f21a958744478359532dea715ed12025-02-03T06:42:54ZengWileyAdvances in Hematology1687-91122023-01-01202310.1155/2023/5593635Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective StudyZahra Malakoutikhah0Farzaneh Ashrafi1Ali Derakhshandeh2Applied Physiology Research CenterDepartment of Internal MedicineDepartment of Internal MedicineAim. The Hyper-CVAD regimen has shown promising results for adult patients with acute lymphoblastic leukemia (ALL), as designed by the MD Anderson Cancer Center (MDACC). This treatment has resulted in a complete remission rate of 92% and a 5-year overall survival of 38%. However, given the diversity of patient demographics and institutional methods, outcomes may differ between various institutions. This study will compare the outcome of adult ALL patients treated with the Hyper-CVAD regimen in Iran with those obtained in the original series presented at the MDACC. Patients and Method. In this retrospective study, we evaluated the 2-year leukemia-free survival (LFS) and the 2-year overall survival (OS) of 70 ALL patients treated between 2014 and 2019 in the Seyed Al-Shohada Hospital in Isfahan, Iran. Results. In total, 59 ALL patients (84.28%) achieved complete remission (CR). The CR rate had statistical differences by bone marrow transplantation (BMT) and WBC count. The 2-year LFS and OS were 40% and 42%, respectively. There were significant differences in LFS and OS by BMT, myeloid marker, and WBC count. Conclusion. The outcome of the traditional Hyper-CVAD regimen in treating adult ALL was not satisfying. More efficient therapies should be applied for the treatment of adult ALL.http://dx.doi.org/10.1155/2023/5593635 |
| spellingShingle | Zahra Malakoutikhah Farzaneh Ashrafi Ali Derakhshandeh Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study Advances in Hematology |
| title | Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study |
| title_full | Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study |
| title_fullStr | Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study |
| title_full_unstemmed | Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study |
| title_short | Prognostic Factors and Outcome of Patients with Adult Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen: A Retrospective Study |
| title_sort | prognostic factors and outcome of patients with adult acute lymphoblastic leukemia treated with the hyper cvad regimen a retrospective study |
| url | http://dx.doi.org/10.1155/2023/5593635 |
| work_keys_str_mv | AT zahramalakoutikhah prognosticfactorsandoutcomeofpatientswithadultacutelymphoblasticleukemiatreatedwiththehypercvadregimenaretrospectivestudy AT farzanehashrafi prognosticfactorsandoutcomeofpatientswithadultacutelymphoblasticleukemiatreatedwiththehypercvadregimenaretrospectivestudy AT aliderakhshandeh prognosticfactorsandoutcomeofpatientswithadultacutelymphoblasticleukemiatreatedwiththehypercvadregimenaretrospectivestudy |